Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2001
12/26/2001CN1327793A Pyrrolo-triazine and pyrimidine compounds
12/26/2001CN1327792A Method for controlling medicine dosage
12/26/2001CN1076728C Derivative of 2-aryl imidazo [2,1-a] isoquinoline and its use
12/26/2001CN1076727C Novel triazolones as apolipoprotein-B synthesis inhibitors
12/26/2001CN1076623C Active component of cordyceps sinensis and its separating method
12/26/2001CN1076619C Moxiburning medicine for acupoint therapy
12/26/2001CN1076611C Exterior-applied medicine 'Yiganzhuanyin liquid' for transforming surface antigen of hepatitis B from positive to negative and its preparing process
12/26/2001CN1076607C Process for preparing pharmaceutical composition containing novel steroid esters
12/26/2001CN1076606C Use of novel steroid esters for preparing medicaments flammatory and anti-allergic activity
12/26/2001CN1076605C Drug for treating hepato biliary diseases
12/26/2001CN1076604C Slow releasing agent of tuduvanine and its preparing method
12/26/2001CA2351215A1 Use of ergothioneine and/or its derivatives as an antiglycation agent
12/25/2001US6333433 Coupling aliphatic aldehyde with alkylamine, reducing imine to secondary amine, reacting with protected hydroxyalkyl halide, deprotecting, quaternizing n-hydroxyalkyl group containing tertiary amine with alkyl halide or tosylate in polar solvent
12/25/2001US6333422 Thermosensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same
12/25/2001US6333421 Capsaicinoide-like substances having ester bond
12/25/2001US6333419 Chromatographic separation method of paclitaxel and cephalomannin
12/25/2001US6333410 Process for the preparation and purification of thiol-containing maytansinoids
12/25/2001US6333399 Preparing preferential binding particles; mix chitin containing microorganism in alkaline solution, mix with mineral acid, mix with second mineral acid solution, neutralize and recover binding particles
12/25/2001US6333361 Pharmaceutical composition containing zafirlukast
12/25/2001US6333357 Behavior chemotherapy
12/25/2001US6333356 Compounds for treating skin conditions
12/25/2001US6333354 Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
12/25/2001US6333353 Nutrients, foods, drugs
12/25/2001US6333352 Method of treating benign positional vertigo
12/25/2001US6333351 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
12/25/2001US6333350 Use of nitric oxide donors and/or substrates or nitric oxide inhibitors for regulating cervical dilatation and extensibility
12/25/2001US6333348 Use of docetaxel for treating cancers
12/25/2001US6333347 Intrapericardial delivery of anti-microtubule agents
12/25/2001US6333346 Aminofuranoneureas or thioureas 4-amino-2(5h)-thiophenones as antitumor agents
12/25/2001US6333345 Methods of using and compositions comprising N-desmethylzolpidem
12/25/2001US6333344 Prolines as antimicrobial agents
12/25/2001US6333343 Diphenyl-triazole derivatives and their use as anti-gestative, immuno-suppressant and anti-tumoral agents
12/25/2001US6333341 Tumor necrosis factor, antiinflammatory agents and analgesics
12/25/2001US6333340 Sulfonamides with oxo, ester or amide groups for vision defects and cognition activators
12/25/2001US6333339 3-Benzylpiperidine
12/25/2001US6333338 Anticoagulants, cardiovascular disorders
12/25/2001US6333337 Potassium channel inhibitors
12/25/2001US6333336 Pyrazolo-pyridine derivatives as ligands for GABA receptors
12/25/2001US6333334 Use of macrolide compounds for the treatment of ARDS
12/25/2001US6333333 Methods for treating proliferative diseases
12/25/2001US6333332 Storage stability
12/25/2001US6333331 Useful in inactivating the human dna repair protein o.sup.6 -alkylguanine-dna alkyltransferase; anticancer agents
12/25/2001US6333328 Serotonin 5-HT3 receptor partial activator
12/25/2001US6333327 6-substituted 5h-indolo(2.3b)quinoxalines
12/25/2001US6333326 For therapy of neurodegenerative diseases selected from stroke, transient ischemic attack, peri-operative ischaemia, global ischaemia following cardiac arrest, and traumatic head injury to brain or spinal cord, epilepsy
12/25/2001US6333325 Method of treating cytokine mediated diseases or conditions
12/25/2001US6333324 For therapy and prophylaxis of matrix metalloproteinases (mmp) or tumor necrosis factor .alpha. (tnf.alpha.), mediated diseases
12/25/2001US6333323 Indole derivatives with antiviral activity
12/25/2001US6333319 Synthetic metal-substituted bacteriochlorophyll derivatives and use thereof
12/25/2001US6333318 Used in therapy; for delivering recombinant proteins into a variety of cells within a patient
12/25/2001US6333317 Regulation of amyloid precursor protein (APP) expression by administration of an estrogenic compound
12/25/2001US6333316 Orally administering to mammal unit dosage of histamine h2 receptor blocker or a proton pump inhibitor and a unit dosage of a bisphosphonate according to a continuous schedule
12/25/2001US6333306 Pharmaceutical combination preparations containing erythropoietin and iron preparations
12/25/2001US6333304 For therapy of arthroses in animals
12/25/2001US6333198 Assaying sample of lamotrigine or a pharmaceutical dosage form comprising lamotrigine in presence of n-(5-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-3-yl)-2, 3-dichlorobenzamide
12/25/2001US6333188 Lactic acid bacteria preparation having biopurification activity
12/25/2001US6333171 CD4 gene regulatory sequences specifically expressed in mature T cells
12/25/2001US6333058 Mixing neem oil with aliphatic hydrocarbon solvent; filtering mixture to separate the filtrate solution from precipitate; contacting filtrate with polar extractant solvent to extract spermicidal agent; removing solvent
12/25/2001US6333057 Composition and method for topical treatment of androgenic alopecia
12/25/2001US6333055 Use of ammonium compounds and/or urea
12/25/2001US6333051 Nanogel networks and biological agent compositions thereof
12/25/2001US6333045 Gatifloxacin or its salt and disodium EDTA to prevent coloration; eye, ear or nose drops
12/25/2001US6333044 For therapy of inflammation and pain of a traumatic or pathologic origin
12/25/2001US6333027 Non-stinging to the eyes
12/25/2001US6333023 For therapy of respiratory disorders
12/25/2001US6333021 For delivery of therapeutically and/or diagnostically active substance, when in suspension in physiologically acceptable carrier useful as delivery vehicles for therapeutically active agents and/or as contrast agents for echographic imaging
12/25/2001US6332883 Spine distraction implant
12/25/2001US6332882 Spine distraction implant
12/25/2001CA2234164C Novel orthosomycins from micromonospora carbonacea
12/25/2001CA2233753C Drug delivery system for two or more active substances
12/25/2001CA2217950C Metered dose inhaler for albuterol
12/25/2001CA2209313C Heterocycle-fused thiazole derivatives
12/25/2001CA2208230C Controlled release formulation (albuterol)
12/25/2001CA2184582C Pharmaceutically acceptable dnase formulation
12/25/2001CA2166517C Cosmetic or dermatologic composition containing at least a ceramide 6
12/25/2001CA2094027C Osteogenic peptides
12/25/2001CA2081348C Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof
12/25/2001CA2068590C Process and intermediates for the preparation of spiro¬isoquinoline-4(1h),3'-pyrrolidine|-1,2',3,5'(2h)-tetrones which are useful as aldose reductase inhibitors
12/25/2001CA2066728C Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
12/25/2001CA2058592C Antibacterial agents
12/25/2001CA2052424C 2-(4-piperidinyl)-1h-pyrido¬4,3-b|indol-1-ones and related compounds, intermediates and a process for their preparation
12/25/2001CA2027023C Inosine/guanosine derivatives
12/22/2001CA2351250A1 Method for stimulating liver regeneration
12/21/2001CA2351125A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
12/20/2001WO2001096879A2 Method and apparatus for monitoring anti-platelet agents
12/20/2001WO2001096586A1 Antisense modulation of c/ebp alpha expression
12/20/2001WO2001096523A2 Polynucleotides related to colon cancer
12/20/2001WO2001096397A2 Cd154 variants and uses thereof
12/20/2001WO2001096388A2 Compositions and methods for the therapy and diagnosis of colon cancer
12/20/2001WO2001096360A1 Antisense modulation of c/ebp beta expression
12/20/2001WO2001096354A1 Combinatorial production of nucleotide and nucleoside (xitp)analogues
12/20/2001WO2001096353A2 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES
12/20/2001WO2001096347A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
12/20/2001WO2001096346A1 Tricyclic compounds as mrp1-inhibitors
12/20/2001WO2001096345A1 Tetrapyrroles
12/20/2001WO2001096343A1 Substituted metal-phthalocyanines, their preparation and the use thereof
12/20/2001WO2001096339A1 Novel telomerase inhibitors
12/20/2001WO2001096338A1 Non-nucleoside reverse transcriptase inhibitors
12/20/2001WO2001096337A1 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
12/20/2001WO2001096336A2 6,5-fused bicyclic heterocycles